Press Enter to search · Esc to close
A major European Heart Journal review reframes excess weight as a driver of the heart's biological aging itself. The implication: weight reduction may be less about preventing one bad day and more about extending healthy years.
A 2025 meta-analysis of 29 randomized trials suggests GLP-1 receptor agonists trim cardiovascular events in non-diabetic adults with obesity — while parallel reviews push the class into PCOS, perioperative care, and an experimental dual-receptor frontier.
Semaglutide and tirzepatide rewrote the metabolic playbook. The pipeline behind them is already bifurcating — and what arrives next will look less like one blockbuster shot and more like a stack.
Three new reviews argue we've been measuring the wrong thing. The real target isn't weight — it's the adipose tissue quietly running your metabolism.
A major new synthesis argues obesity is not just a metabolic condition but a fundamentally altered immunological state — reshaping how we think about GLP-1s, weight loss, and the body's defenses.
New survey and claims data suggest a quiet mismatch in cardiometabolic care: physicians may be undercounting how much weight and risk these drugs move, while many eligible adults never start them.
Phase III data on IcoSema and fresh SURMOUNT analyses of tirzepatide are rewriting what 'best-in-class' looks like for metabolic and obesity care.
As GLP-1 demand outpaces supply, fresh data from Karachi, a critical review of Asian-descent dosing, and an early trial of a novel Chinese molecule hint at a more personalized future for metabolic care.
Weekly semaglutide rewrote metabolic medicine. The pipeline behind it — a small-molecule pill, a twin-receptor agonist, and an injectable depot that lasts weeks — is now coming into focus.